Image source: The Motley Fool.
TherapeuticsMD Inc (TXMD -1.59%)
Q3Â 2019 Earnings Call
Nov 6, 2019, 4:30 p.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good afternoon, ladies and gentlemen, thank you for joining us for the TherapeuticsMD Third Quarter 2019 Financial Results Conference Call. Following prepared remarks from the Company, we will open the call for questions. I would now like to turn the call over to TherapeuticsMD's, Vice President of Investor Relations, Nichol Ochsner. Nichol?
Nichol Ochsner -- Vice President of Investor Relations
Good afternoon everyone, thank you for joining today to discuss our third quarter financial results and business update. This afternoon TherapeuticsMD issued a press release announcing our third quarter financial results. The press release is available on the Company's website therapeuticsmd.com in the Investors and Media section. On today's call, from TherapeuticsMD, are Chief Executive Officer, Robert Finizio; Chief Financial Officer, Dan Cartwright; and Chief Commercial Officer, Dawn Halkuff.
I would like to remind everyone that certain statements made during this conference call may be forward-looking statements. Such forward-looking statements are based upon current expectations and there can be no assurance that such statements may be realized -- that the results contemplated in these statements will be realized. Actual results may differ materially from statements due to a number of factors and risks, some of which are identified in our press release and our annual quarterly and other reports filed with the SEC.
These forward-looking statements are based on information available to TherapeuticsMD today and the Company assumes no obligation to update statements as circumstances change. An audio recording and webcast replay for today's conference call will also be available online in the Investors and Media section of the website. For the benefit of those who may be listening to the replay or archived webcast, this call was held and recorded November 6, 2019. With that, I'll turn the call over to TherapeuticsMD CEO, Rob Finizio.
Robert Finizio -- Chief Executive Officer, Co-Founder, and Director
Thanks, Nichol. Good afternoon everyone and thank you for joining today's call. We are pleased to report a strong third quarter with net revenues that came in at the upper end of our financial guidance. This was led by growth in product sales from our FDA-approved products, reflecting continued successful commercial execution. Let me now turn the call over to our Chief Financial Officer, Dan Cartwright, to review our Q3 financial results in more detail.
Dan Cartwright -- Chief Financial Officer
Thanks, Rob. Third quarter 2019 financial results are included in the press release issued today. Turn now to Slide 3. I'm going to focus on sequential trends from our second to third quarters which we believe is a better comparison as we discuss our performance. The combination of net revenue from product sales and licensing brings our overall net revenue for the third quarter to $23.7 million compared with $6.1 million for the previous quarter.
Slide 4, shows our third quarter product revenue performance compared to our guidance. Third quarter net revenue of our FDA-approved products was $5.7 million and at the upper end of our financial guidance. Net revenue from our prescription prenatal vitamin business was $2.25 million for the third quarter of 2019 coming in above our financial guidance. Total product net revenue came in at the upper end of our guidance at $8.2 million. Additionally, we had $15.5 million in revenue from a licensing agreement for IMVEXXY and BIJUVA from Theramex. We are also eligible to receive additional payments and royalties under this license in the future.
The chart on Slide 5 shows that we continue to have strong growth for IMVEXXY. Net revenue for IMVEXXY was $4.8 million for the quarter, which continued the trend of net revenue growing at a faster pace than growth in units. As you can see, IMVEXXY net revenue increased 53% third quarter over second quarter compared to a 27% increase in units over the same period.
Turn to Slide 6, we continue to have strong growth for BIJUVA as well. Net revenue for BIJUVA was approximately $490,000 for the quarter, in line with our expectations, we continue to see net revenue per unit, which will be discussed later.
Now move to Slide 7, we launched ANNOVERA late in the third quarter and recorded sales of $400,000. We are encouraged to see initial average net revenue at $1250 per unit.
Turn to slide 8, as expected, the total operating expenses for the third quarter of 2019 increased compared to the second quarter of 2019 due to the increase in commercialization expenses for the launch of both IMVEXXY and BIJUVA, and the preparation for the launch of ANNOVERA. SG&A expenses for the third quarter of 2019 were $45.1 million compared to $41.4 million for the previous quarter.
Turning to the bottom line, our net loss for the third quarter of 2019 was $32 million or $0.13 per basic and diluted share, which included license revenue of $15.5 million, while the net loss in the second quarter of 2019 was $55.2 million or $0.23 per basic and diluted share. Excluding the license revenue of $15.5 million in the third quarter, our net loss would have been $47.5 million compared to a net loss of $55.2 million for the second quarter of 2018.
Now move to Slide 9, we finished the third quarter of 2019 with a $155.3 million in cash, compared with $183 million at June 30 of 2019. As shown on Slide 10, you can see, after the end of the quarter, we completed an equity raise that netted the company $77 million. Adding the proceeds from the equity raise to the cash at quarter end would have resulted in a proforma cash balance of $232 million.
Please turn to Slide 11. Our company has taken significant steps this year to raise additional non-dilutive capital to support the commercialization of our three FDA-approved products. We have the opportunity to pull down another $100 million from our term loan from TPG Sixth Street Partners also known as TSSP in two $50 million tranches. For the first $50 million tranche, we have begun discussions with TSSP about revising the draw trigger that is tied to the FDA's decision on the 19th category for ANNOVERA. This is due to the positive ANNOVERA launch trends including rapid commercial insurance coverage and strong commercial net revenue per unit, as well as a potential for the FDA's decision to come after the fourth quarter of this year.
TSSP has informed us that it is open to considering a revised -- a revision, excuse me, to the terms and timing of this draw trigger. There is no assurance that we or TSSP will agree to any such revision. The second $50 million tranche would be available to us upon achieving $11 million in net revenue from IMVEXXY, ANNOVERA, and BIJUVA for the fourth quarter of 2019 after our year-end audit financials are delivered in late February, 2020.
Please turn to slide 12. At this time, we reaffirm our product net revenue guidance for the fourth quarter of 2019. This reiteration of FDA-approved product net revenue guidance is important because it affirms our confidence that we will be able to access the additional $50 million in capital from TSSP.
I would like to now turn the call over to Dawn Halkuff, our Chief Commercial Officer.
Dawn Halkuff -- Chief Commercial Officer
Thanks, Dan. Let's turn to Slide 13. Now that you've seen our achievements in Q3, I want to take you through how we are going to achieve our fourth quarter net revenue guidance of $11 million to $13 million for our FDA-approved products.
Let's move first to IMVEXXY on Slide 14. You can see on the right hand side of the slide, the adjudication rates shown in blue and the calculated net revenue per unit shown in green, both continue to rise. What you can see is that as adjudication rates have gone up, the calculated net revenue per unit has moved on the same trend as adjudication rates demonstrating that adjudication rates continue to be a good indicator of growth of net revenue per unit.
In October, we began our co-pay optimization process by moving our cash pay program from $35 to $50. We did this as we achieved our goal in Q3 of broad commercial coverage of approximately 70%. We are pleased with the results of our first month of transition and importantly, we are seeing the immediate impact on adjudication and calculated net revenue per unit. October shows adjudication rates at approximately 52% which is a 14% increase over Q3. Based on the trends that we have already experienced in October, we anticipate calculated net revenue per unit to increase in the fourth quarter to a range of $48 to $52 per unit. Given this even if TRXs were to stay relatively flat for the fourth quarter, IMVEXXY could produce a minimum of $7 million of revenue.
For the remainder of the quarter, we will focus on the following growth drivers for IMVEXXY. First, hyper-targeting of prescribers that are adopting IMVEXXY for their commercial patients and therefore pulling through where we have strong commercial coverage.
Please turn to Slide 15. With the addition of CVS who began adjudicating in September, we are now adjudicating commercial patients at 72% in the month of October. Other important levers to support share growth within those prescribers is continued medical education as well as direct-to-consumer advertising, which began in late August. In closing for IMVEXXY, I want to announce we now have an agreement with Aetna thus completing our commercial payer cycle.
Let's move to BIJUVA on Slide 16. As you can see on the chart, adjudication rates shown in blue, are now at 56% in October, an 11% increase over third quarter. On October 1, we also started the same $35 to $50 cash pay optimization process and continue to see growth for BIJUVA during this transition. Given these changes along with the trends that we have already experienced in October, we anticipate calculated net revenue per unit to increase in the fourth quarter to a range of $40 to $46 per unit.
Moving to Slide 17. The remainder of the quarter will focus on the completion of the commercial payer process pulling through the access we currently have now at 55% unrestricted commercial access with Cigna adjudicating in September and Envision who will begin adjudication in November.
We are now adjudicating commercial patients at 62% in the month of October. In addition, we will work to drive growth through the continued focus of the sales organization on high decile prescribers along with our key account management team focusing on selling the 142 live BIO-IGNITE location to adopt BIJUVA. Finally, we expect to submit a New Drug Application efficacy supplement for the 0.5 100-milligram dose of BIJUVA to the FDA for approval which if approved, could launch toward the end of 2020.
Now let's move to ANNOVERA on Slide 18. As a reminder, we started a soft launch in late September, with only 36 of our existing sales representative and sales management selling the product to provide existing loan environment to support fast uptake for our full launch in Q1, 2020.
Turn to Slide 19. In addition to the sales focus, we continue to build commercial access, which in a short period of time is now at 62% unrestricted coverage with coverage by the six of the top-10 commercial payers.
Turning to Slide 20. We have also started consumer marketing and are working with PillPack, an Amazon company to quickly fill demand and we'll continue to pilot programs in the contraceptive category providing more convenient options for patients to obtain their birth control.
As a reminder, ANNOVERA represents the only long-lasting reversible procedure-free contraceptive option for women. Early feedback from doctors indicate that ANNOVERA is still in an important unmet need in the marketplace where long-acting reversible contraceptive or LARC are the only growing segment. Based upon that feedback and patient demand trends today, we believe we will generate sales of a minimum of 2800 units in the fourth quarter with the calculated net revenue per unit in the range of $1250 to $1400. Putting this altogether, you can see why we are confident we can meet our fourth quarter expectations.
Please move to Slide 21. I'd like to end by stating, with the initial launch of ANNOVERA, all products in our portfolio are now launched. Our commercial infrastructure build and commercial coverage swung across the portfolio, giving us a strong foundation to execute on future growth plans. I'd now like to turn the call back to Rob.
Robert Finizio -- Chief Executive Officer, Co-Founder, and Director
Thanks, Dawn. We've shared a lot of information today, but I want you to take away a few key points. First, we had a solid Q3 that hit the upper end of our guidance. In addition, we reaffirmed our Q4 guidance and once achieved, should enable an additional $50 million in non-dilutive funding. We've opened a dialog with TPG Sixth Street Partners on extending our draw trigger related to the 19th category and created significant momentum in the women's health marketplace that will take us into 2020 and beyond. I'd now like to open up the lines for questions.
Questions and Answers:
Operator
[Operator Instructions]. Your first question comes from the line of Annabel Samimy of Stifel. Your line is now open.
Annabel Samimy -- Stifel -- Analyst
Hi, thanks for taking my questions and congratulations. I have several here. So, first on just the FDA classification. I think you mentioned that it was possibly delayed for the restructuring. I missed the first part of your comment, so I apologize if I'm asking something you've already talked about. But have you actually had communication with the FDA that leads you to believe the classification will be delayed or is it not happening at all and I also understand that this restructuring is happening in February. So why is that impacting the decision? That's the first question.
The second question I have is, what kind of impact the move of going from a $35 to $50 co-pay -- what has had -- what kind of impact is that having on prescription fulfillment and walkaways, is that level OK for patients?
And then finally, just looking at BIJUVA, the net was higher third quarter from second quarter, but only modestly and I guess not really in proportion with the increase in adjudication. So if you could provide some color there. And I guess I'll get back in the queue if I have more. Thanks.
Robert Finizio -- Chief Executive Officer, Co-Founder, and Director
Okay. Hey, Annabel. It's Rob. So 19th category. Yes, we are in contact with the FDA, we -- the restructuring of the division is certainly changing a lot there. And I'm sure you seeing with other companies, there's a lot going on there. So we do believe the decision will push into the next year and thus we -- that financing, and we definitely still believe we qualify for the 19th category, but that is the FDA's decision, and we do think they will make it, they will make the decision either for us or against us. We do think we qualified for it, though, just to be clear. And I think that answers all your questions on that. I'm going to pass it to Dawn, if it's OK on the $50 for cash pay patients question.
Dawn Halkuff -- Chief Commercial Officer
Sure. Hi, Annabel.
Annabel Samimy -- Stifel -- Analyst
Hi.
Dawn Halkuff -- Chief Commercial Officer
So the question you asked was, what has been the impact of the $35 to $50. So just to provide some context, we made that change on October 1. And just as a reminder, just to go back, the reason we have the strategy we do is we have this open access -- Open Access Program, which shows -- which we knew would unlock a lot of HCP prescribing early on before commercial coverage came on. And so the move to the $50 was timed with achieving that broad national commercial coverage. And so, and really what we like to see are HCPs still prescribing or healthcare professional still prescribing because that is where the end of the access -- that's why we have the open access strategy, and the answer to that is yes. We're still growing HCP prescribing.
That said, we have seen some drop-off from the $35 to $50 of those patients were it did -- where that wasn't an acceptable price to them, but the reality is, those are the more unprofitable patients that don't have the coverage. And so what you're starting to see us do is shift to those more profitable patients and again because of the H -- the healthcare professionals, we're still growing those prescribing, I'm very confident in that rebound in particular as we are also hyper targeting those that are adopting for commercial coverage and we have direct-to-consumer advertising to support that growth.
So we did see some drop-off. I do expect to see it rebound and again those that we're losing are the folks without coverage, which is where we need to set ourselves up for the long-term.
Robert Finizio -- Chief Executive Officer, Co-Founder, and Director
Yeah. Annabel, we only have 10% market share approximately. We're not done. We strongly believe we will continue to grow the market and our share of the market.
Annabel Samimy -- Stifel -- Analyst
Okay and just last question on the BIJUVA and that...
Robert Finizio -- Chief Executive Officer, Co-Founder, and Director
Yeah.
Dawn Halkuff -- Chief Commercial Officer
Yeah.
Annabel Samimy -- Stifel -- Analyst
Yeah, sorry.
Dawn Halkuff -- Chief Commercial Officer
Yeah. Your question Annabel, why isn't. Yeah, go ahead.
Annabel Samimy -- Stifel -- Analyst
Yeah, just on BIJUVA, we didn't see much incremental increase in the gross whenever we saw a bigger step up in the adjudication rates. So what -- it's a kind of mismatch with the proportionality there. So just a little color, it would be great. Thanks.
Dawn Halkuff -- Chief Commercial Officer
And there, because BIJUVA isn't yet in the place of where IMVEXXY was, whereas a much higher coverage rates. So what we would expect is that gross to net will catch up similar to IMVEXXY as that coverage rises.
Annabel Samimy -- Stifel -- Analyst
Okay. Can I sneak in one more on ANNOVERA?
Robert Finizio -- Chief Executive Officer, Co-Founder, and Director
Yeah, of course, absolutely.
Annabel Samimy -- Stifel -- Analyst
You mentioned that the ANNOVERA net price is, I think, set to increase, I mean, over time. I guess even for the fourth quarter you have $1250 to $1450 so with more payers getting on board, usually we have seen net's[Phonetic] going down, but this is actually going up. So I guess, maybe you can help us understand the dynamics there.
Robert Finizio -- Chief Executive Officer, Co-Founder, and Director
Yeah, I mean it's just been a very pleasant surprise, I mean as you can see as fast as BIJUVA is going, which is much faster than IMVEXXY got coverage, ANNOVERA is like something nobody here has seen so, about four weeks in, 62-plus percent coverage and so many of the payers don't require a co-pay, and that would obviously, if we had to use co-pay cards, would impact our net's, given the type of drug it is and how clearly we believe it's a new method. The rebates are also -- are very few and far between. So it's a $2000 WAC price just to remind everyone, it's about 5% less than a year worth of NuvaRing. So net's that the company is experiencing and the rapid adoption of this coverage is, in our opinion, just staggering. So we assume that will improve as we go forward and it looks really, really healthy. So we're more than pleased. Does that addresses your question?
Annabel Samimy -- Stifel -- Analyst
Yeah, that's great. Thank you.
Robert Finizio -- Chief Executive Officer, Co-Founder, and Director
Thank you.
Operator
Your next question comes from the line of Louise Chen of Cantor Fitzgerald. Your line is now open.
Unidentified Participant
This is a Sedan Louis Nathan[Phonetic] in for Louise Chen. Thanks for taking our questions. I guess I have a couple here. So first I wanted to touch on the cash runway, I noticed that you have the $77[Phonetic] million that you're able to tap into, and then half of the tranches coming up forward prior to hitting the $50 million tranche in 4Q, '19 and then the second one, what is the cash run rate currently for which you have now?
And then secondly on ANNOVERA. If you're able to gain the 19th amendment it would in that case -- is there a ability to increase the price pass to $1400, or is there any clarity in the pricing that we can get, if it can go any higher or not? So, those are [Indecipherable]. Thanks,
Robert Finizio -- Chief Executive Officer, Co-Founder, and Director
Yeah, OK. So this is Rob and I'm going to pass a little bit to Dan as well, Dan Cartwright our CFO. All right, so as far as the 19th category, what we are very happy to experience and trying to make crystal clear in this call is that the net -- we originally believed the 19th category designation would significantly improve our net's for a number of reasons, one is co-pays. With the 19th category, there would be no co-pays naturally. It would also help us get coverage quickly and also rebates. Given the pleasant surprise adoption, very few and far between rebates and very few co-pays, the 19th category's value at this point would be for the $50 million loan draw from TPG Sixth Street Partners more so than the impact of the 19th category would have on the net revenue per unit to the company.
Just -- I just want people to realize that if there is a co-pay, we plan on couponing[Phonetic] it down to zero for patients. All right. So that's our intent and we don't have to do much of that at all. There is a number of ways to get to a very strong robust net revenue per product with the 19th category, was our belief. And we're kind of there without it. So it's just a real pleasant surprise. And so I think the takeaway I would have if I were sitting in your seat is basically the 19th category's value to us is the $50 million draw with TPG and then as far as cash goes, we've got with the raise, we had 155[Phonetic] at the end of the quarter, with the $77 million in the range. Because it's a total of 232[Phonetic], the potential, and I think we laid the numbers out to show our confidence, we reiterated the guidance, we affirmed our guidance for Q4 which would hitting that $11 million would give us the ability to draw another $50 million from our loan agreement with TPG Sixth Street Partners.
And then if the 19th category is designated and then another $50 million there. We are in discussions with them as well as we stated. But I can't get into a lot of depth there until we get to the end of the job. Okay?
Sudan Loganathan -- Cantor Fitzgerald -- Analyst
Okay, great, thanks guys.
Robert Finizio -- Chief Executive Officer, Co-Founder, and Director
Thank you.
Operator
[Operator Instruction] Your next question comes from the line of Chris Schott of JP Morgan. Your line is now open.
Unidentified Participant
This is actually Katerina[Phonetic] on for Chris. Thank you for taking our questions. And my first one is, can you talk about the uptick that you're seeing so far with BIJUVA specifically in the compounding channel and just your experience with the compounder so far. Has update -- has up -- sorry, has uptake been what you expected and how do you see it ramping in the coming quarters?
Unidentified Participant
And the second question is, can you talk about the traction you're seeing with your DTC campaign for IMVEXXY. Is this something that you're open to be putting more investment behind in 2020 and beyond? Thank you.
Robert Finizio -- Chief Executive Officer, Co-Founder, and Director
Sure, Katerina. So this is Rob and then I'll hand it off to Dawn. So as far as, BIO-IGNITE program goes, we are up to 142 pharmacies that are live and up on IMVEXXY. We have about half of those that were going into very quickly already on BIJUVA, but we're just starting that now that we've had these last couple of payers come on in the last few weeks, and we expect more in the future here in the near future, by the way. So the whole idea with BIO-IGNITE is to make sure for this class of trade, we had solid reimbursement in place, so we don't lose net revenue on any of those prescriptions. So I think you'll see throughout the quarter, we'll bring all those 142 live and hopefully we'll add additional pharmacies this quarter as well and then have it fully operational toward the end of Q4.
The next question, i'm going to hand off on DTC to Dawn.
Dawn Halkuff -- Chief Commercial Officer
Thanks for the question. Katerina, so your question was how is DTC going and are we going to invest and continue it for 2020 and so we're early, we launched DTC at the end of August, largely in print, digital and social media. What we look at as early indicators are, are we getting the traffic to the website and I can tell you from early data that we're seeing significant growth on the website so that, what that means to us is that the message is on target and their significant interest. But we will need to wait a few months to see the ROI's of what we're putting out there. In terms of, are we going to invest in 2020, the answer to that is yes. We're putting together our 2020 plans now, but we know we have a solid campaign and we'll look to do IMVEXXY DTC throughout the year, but as we've always said, with all of our consumer campaigns that we're building, we do a test and learn strategy, so we can get the optimal return on our investment. But yes, we will be continuing.
Robert Finizio -- Chief Executive Officer, Co-Founder, and Director
And I think you can -- you can intertwine that with the cash pay $35 raised to $50, right. So what that's showing us is what -- number one, that brings you in the profitable patients you want from people that are uninsured. But it also helps the demographic of who is willing to pay here which you can intertwine with your direct-to-consumer targeting as well as your physicians, right. And that's -- we're really, really pleased that a full month been to that improvement, there has been a little bit of slowing, but the growth is not done and we have a number of ways to continue that growth. So, but I'll just be much more profitable patients and we expect that this quarter. So the whole thing kind of intertwines as one plan as Dawn says between all products in this fashion except ANNOVERA where we're really happy that we're not using many co-pay cards at all. Right?
Dawn Halkuff -- Chief Commercial Officer
Yeah, correct.
Robert Finizio -- Chief Executive Officer, Co-Founder, and Director
So we have less patient information and less immediate feedback on the units. But the upside is we have much higher net margins.
Unidentified Participant
Great, thank you.
Robert Finizio -- Chief Executive Officer, Co-Founder, and Director
Thank you.
Operator
[Operator Instructions]. Your next question comes from the line of Douglas Tsao of HCW. Your line is now open.
Douglas Tsao -- HCW -- Analyst
Hi, good afternoon. Thanks for taking the questions. Just, I know we're awaiting the decisions for IMVEXXY for Part D. Rob, I'm just curious how important is Part D for that just sort of optimize or maximize that product opportunity?
Robert Finizio -- Chief Executive Officer, Co-Founder, and Director
Doug, thanks for joining and welcome. So we appreciate your support here with the company. So, thank you. So Part D is important for the next to get up to the $100 range we talked about for IMVEXXY. So we remain positive that we will get most -- we may not get them all on the Part D side, but we really think we'll do well and it is very important for that patient type. If you take a look close look at the slides, I think you'll see that we have improved our adjudication in the Part D segment significantly up and we're close to where it is, where our coverage is. So in essence, we basically have United, we have Kaiser, but no access there and we're hoping to get access shortly there, but that 20% United has, we have about 17% of that adjudicating and we expect that to continue to improve. And that, actually, Doug, I'm glad you brought that up because that one thing my CFO asked me to mention here on the last question is, we are at a 100% adjudication for IMVEXXY, I'm sorry for ANNOVERA not IMVEXXY, I wish we were.
So, for ANNOVERA, just to answer the last question, that's written down here, we're at 100% for ANNOVERA in adjudication. So when do I start to answer your question, very important, we need Part D. That is, as you know, it's 31% of our total prescriptions, approximately. And we have all of those vision for the 2021 year, which should start on January 1 and all of those decisions will be made good or bad, for us before January 1 and we think we'll do pretty well. Anything you want to add to.
Dawn Halkuff -- Chief Commercial Officer
Yeah. Just with the ANNOVERA, as you're mentioning that 100% adjudication and the high revenues per units. One thing we didn't mention is that as we're doing 2020 planning, we are moving the ANNOVERA full launch with the 200 sales representatives up to the beginning of the first quarter in January, given the results that we're seeing and that demand. So I think that will really put us in a good start to the beginning of the year.
Douglas Tsao -- HCW -- Analyst
Thanks. And then just one follow-up question on ANNOVERA. I'm just curious in terms of the demand that you're seeing and the interest you're seeing from physicians today, what characteristics are they talking about are sort of seem to be gaining the most traction in the marketplace?
Dawn Halkuff -- Chief Commercial Officer
Yeah, so I mean it's been -- we've been out there for about a month and it's been a really interesting start. So there are some things that I haven't seen in my career with pharmaceutical launches in this space. One is because the product is so unique, our sales representatives are getting the time to really describe the product, which is wonderful. And it also just shows the uniqueness of the product and the unmet need that it's bringing. Where we're seeing sort of the features that are important is exactly what you would expect, which is, it is the only procedure-free reversible contraceptive in the category. And so because of that the healthcare professionals -- they talk, they've got the time for us to really discuss that. And in terms of the type of doctors that we're seeing healthcare professionals that we're seeing that are interested in the product, I mean, it's across the board, but really one insight that's coming to us is, not every physician inserts IUDs and so because of that where we're seeing lower IUD usage or no IUD usage at all, they are really seeing that this is a product that they can offer their patients and keep the patient in that office who wants the long-term option. So really good early results and we feel really bullish for the future.
Douglas Tsao -- HCW -- Analyst
Okay, great. Thank you.
Dawn Halkuff -- Chief Commercial Officer
Your'e welcome.
Operator
At this time, I would like to turn the conference back to TherapeuticsMD's CEO, Rob Finizio for closing remarks.
Robert Finizio -- Chief Executive Officer, Co-Founder, and Director
I want to thank everybody for joining the conference call and appreciate your time and we look forward to speaking with you again next quarter. Thank you.
Operator
[Operator Closing Remarks]
Duration: 36 minutes
Call participants:
Nichol Ochsner -- Vice President of Investor Relations
Robert Finizio -- Chief Executive Officer, Co-Founder, and Director
Dan Cartwright -- Chief Financial Officer
Dawn Halkuff -- Chief Commercial Officer
Annabel Samimy -- Stifel -- Analyst
Unidentified Participant
Sudan Loganathan -- Cantor Fitzgerald -- Analyst
Douglas Tsao -- HCW -- Analyst
